Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference

    Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare
                                  Conference

PR Newswire

DUBLIN, Jan. 2, 2013

DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
announced today that the company will webcast its presentation at the 31st
Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January
8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT). 
Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals,
will present an overview of the company and provide a business and financial
update.

The webcast can be accessed from the Investors section of the Jazz
Pharmaceuticals website at www.jazzpharmaceuticals.com.  An archived version
of the webcast will be available at the same location for at least one week
following the presentation.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia
chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR®
(fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of
the U.S., Jazz Pharmaceuticals also has a number of products marketed by its
international division, EUSA Pharma. For further information, see
www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals plc

Website: http://www.jazzpharma.com
Contact: William Craumer, Director, Investor Relations, Jazz Pharmaceuticals,
Ireland, + 353 1 634 3211, or U.S., + 1 650 496 2750